#BitMineAdds111942ETHInOneWeek The New Jersey Bio-Pharma Trend

You hit the nail on the head regarding the local trend. New Jersey isn't seeing an isolated incident; it's seeing a sector-wide margin defense program. Big Pharma is dealing with impending patent cliffs (like J&J preparing for generic competition against its blockbuster drug Stelara), forcing everyone to ruthlessly optimize corporate footprints:
Novartis: Rolling out its third round of layoffs this year at East Hanover (76 more employees), continuing a multi-year global overhead reduction.
Bristol Myers Squibb: Cutting heavily at Lawrenceville as part of a massive strategy to claw back over $2 billion in operating costs by 2027.
From a trading perspective, keeping an eye on the private equity consortiums forming for that $20 billion DePuy bid is key. If a deal closes, the immediate cash infusion and structural margin jump could be a solid catalyst for J&J ($JNJ) to fund its next wave of high-margin cardiovascular or oncology acquisitions.
Great share—this is exactly how the game is played when a sector transitions from expansion to capital preservation!